25842-32-4

Basic information

• Product Name: 2-(4-BENZYLPIPERIDINO)-1-ETHANAMINE
• Synonyms: ART-CHEM-BB B024998;2-(4-BENZYL-PIPERIDIN-1-YL)-ETHYLAMINE;2-(4-BENZYLPIPERIDINO)-1-ETHANAMINE;AKOS B024998;1-(2-Aminoethyl)-4-benzylpiperidine;2-(4-Benzylpiperdin-1-yl)ethylamine;2-(4-benzylpiperidin-1-yl)ethanamine(SALTDATA: FREE);1-(2-Aminoethyl)-4-benzylpiperidine, {[1-(2-Aminoethyl)piperidin-4-yl]methyl}benzene
• CAS NO: 25842-32-4
• Molecular Formula: C₁₄H₂₂N₂
• Molecular Weight: 218.34
• Mol File: 25842-32-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 130-131°C 3mm
• Flash Point: 141.8 °C
• Appearance: /
• Density: 1.005 g/cm³
• Vapor Pressure: 0.000158mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: 2-8°C
• PKA: 10.21±0.10(Predicted)
• CAS DataBase Reference: 2-(4-BENZYLPIPERIDINO)-1-ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BENZYLPIPERIDINO)-1-ETHANAMINE(25842-32-4)
• EPA Substance Registry System: 2-(4-BENZYLPIPERIDINO)-1-ETHANAMINE(25842-32-4)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 2735
• HazardClass: IRRITANT
• Hazardous Substances Data: 25842-32-4(Hazardous Substances Data)

Usage

General Description

2-(4-benzylpiperidino)-1-ethanamine is a chemical compound with the molecular formula C16H23N. It is also known as 4-benzylpiperidin-1-yl)ethylamine and is a member of the amphetamine class of compounds. This chemical has a piperidine ring structure with a benzyl group attached, and an ethylamine side chain. It is commonly used as a precursor in the synthesis of various pharmaceuticals and research chemicals, as well as in the development of novel psychoactive substances. It may also have potential applications in the field of medicinal chemistry and drug discovery. Due to its structural similarity to amphetamine, it is likely to have stimulant and psychoactive effects, but further research is needed to fully understand its pharmacological properties and potential uses.

InChI:InChI=1/C14H22N2/c15-8-11-16-9-6-14(7-10-16)12-13-4-2-1-3-5-13/h1-5,14H,6-12,15H2

Upstream product

• 25842-31-3 2-(4-benzylpiperidin-1-yl)acetonitrile 
• 31252-42-3 4-benzylpyperidine 
• 182223-59-2 2-(2-(4-benzylpiperidin-1-yl)ethyl)isoindoline-1,3-dione 

Downstream Products

• 100221-96-3 N-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-2-chloro-benzamide 
• 86922-28-3 2-Isopropyl-11-oxo-11H-pyrido[2,1-b]quinazoline-8-carboxylic acid [2-(4-benzyl-piperidin-1-yl)-ethyl]-amide 

Relevant articles and documents

Sigma receptor ligands carrying a nitric oxide donor nitrate moiety: Synthesis, in silico, and biological evaluation

-

Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment

G-quadruplex stabilizers are an established opportunity in anticancer chemotherapy. To circumvent the antiproliferative effects of G4 ligands, cancer cells recruit PARP enzymes at telomeres. Herein, starting from the structural similarity of a potent G4 ligand previously discovered by our group and a congeneric PARP inhibitor, a library of derivatives was synthesized to discover the first dual G4/PARP ligand. We demonstrate that a properly decorated thieno[3,2-c]quinolin-4(5H)-one stabilizes the G4 fold in vitro and in cells, induces a DNA damage response localized to telomeres, inhibits PARylation in cells, and has an antiproliferative effect in BRCA2 deficient tumor cells.

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.